首页> 外文期刊>Annals of the New York Academy of Sciences >Tissue protein biomarker candidates to predict progression of esophageal squamous cell carcinoma and precancerous lesions
【24h】

Tissue protein biomarker candidates to predict progression of esophageal squamous cell carcinoma and precancerous lesions

机译:组织蛋白生物标志物候选物可预测食管鳞状细胞癌和癌前病变的进展

获取原文
获取原文并翻译 | 示例
       

摘要

Esophageal squamous cell carcinoma (ESCC) is one of the most predominant malignancies worldwide. The 5-year survival rate is still relatively low due to few symptoms presenting with the early disease, diagnosis at middle to late stage, and high risk of recurrence after therapy. Novel protein biomarkers for early detection and treatment of ESCC have the potential to reduce incidence and mortality rates, and significantly prolong the 5-year survival rate. To date, several ESCC biomarkers are being investigated for screening, diagnosis, and treatment to decrease the disease burden. This review summarizes recent developments in candidate protein biomarkers for early diagnosis, predictors for precancerous disease progression, and prognosis of ESCC. Protein biomarkers that enable identification of the different pathologic grades of ESCC will need to be identified. ESCC biomarkers have the potential to improve screening and treatment strategies; multicenter prospective studies with large sample sizes will be required to confirm the usefulness of these candidate biomarkers.
机译:食道鳞状细胞癌(ESCC)是全球最主要的恶性肿瘤之一。由于早期疾病,中晚期诊断以及治疗后复发的风险较高,因此5年生存率仍然相对较低。用于ESCC的早期检测和治疗的新型蛋白质生物标记物有可能降低发病率和死亡率,并显着延长5年生存率。迄今为止,正在研究几种ESCC生物标志物,以进行筛查,诊断和治疗以减轻疾病负担。这篇综述总结了用于早期诊断的候选蛋白质生物标志物,癌前疾病进展的预测因子以及ESCC预后的最新进展。需要鉴定能够鉴定ESCC的不同病理学等级的蛋白质生物标志物。 ESCC生物标志物具有改善筛选和治疗策略的潜力;需要进行大样本量的多中心前瞻性研究,以确认这些候选生物标志物的有用性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号